UNSPSC 51384100: Nonsteroidal anti inflammatory phenylbutyrates

Nonsteroidal anti inflammatory drugs made from a family of carboxylic Acids consisting of phenylbutanoic acid (phenyl + butyrate or butyric acid).

UNSPSC 51384100 Nonsteroidal anti inflammatory phenylbutyrates is a Class code that in recent state and local procurement activity covers a broader pharmaceutical and medical supply procurement scope than its nominal name suggests. Recent solicitations show state and local buyers using this code to acquire naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and to explore direct-to-manufacturer prescription fulfillment models. The work ranges from routine commodity purchasing of established pharmaceutical products to exploratory market intelligence gathering around alternative pharmacy benefit delivery mechanisms. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves participating state and local government facilities across multiple states including Oregon).

Recent opportunities span Florida, Texas, and Minnesota-led multi-state cooperative purchasing. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a response deadline of July 26, 2023, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs and alternative contracting models outside traditional pharmacy benefit managers and group purchasing organizations, with no formal award or budget identified at the information-gathering stage. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring products to be available by May 15, 2026 and effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and the remainder on fixed pricing, administrative compliance, EDI capability, and fee structure agreement.